New granule drug hopes to shrink NF1 tumors in toddlers
NCT ID NCT05309668
First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tests a new granule (sprinkle) form of the drug selumetinib in 36 children aged 1 to under 7 years who have neurofibromatosis type 1 (NF1) with painful, inoperable tumors called plexiform neurofibromas. The goal is to find the right dose, check safety, and see if the drug can shrink these tumors. Children take the medicine by mouth twice daily, and the study monitors side effects and tumor changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS TYPE 1 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Akron, Ohio, 44308, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Richmond, Virginia, 23219, United States
-
Research Site
Hamburg, 20246, Germany
-
Research Site
München, 80337, Germany
-
Research Site
Tübingen, 72076, Germany
-
Research Site
Milan, 20133, Italy
-
Research Site
Rome, 00165, Italy
-
Research Site
Nagoya, 466-8560, Japan
-
Research Site
Setagaya City, 157-8535, Japan
-
Research Site
Rotterdam, 3015 GD, Netherlands
-
Research Site
Moscow, 119620, Russia
-
Research Site
Moscow, 125412, Russia
-
Research Site
Barcelona, 08950, Spain
-
Research Site
Madrid, Spain
Conditions
Explore the condition pages connected to this study.